Publications by authors named "R B Mannon"

Background: Sex, as a biological construct, and gender, defined as the cultural attitudes and behaviours attributed by society, may be associated with allograft loss, death, cancer, and rejection. Other factors, such as recipient age and donor sex, may modify the association between sex/gender and post-transplant outcomes.

Objectives: We sought to evaluate the prognostic effects of recipient sex and, separately, gender as independent predictors of graft loss, death, cancer, and allograft rejection following kidney or simultaneous pancreas-kidney (SPK) transplantation.

View Article and Find Full Text PDF

Background: Posttransplant diabetes mellitus (PTDM) is an important complication for solid organ transplant recipients (SOTRs). COVID-19 has been associated with an increased risk of incident diabetes in the general population. However, the association between COVID-19 and new-onset PTDM has not been explored.

View Article and Find Full Text PDF

The XVI-th Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from 19th-23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30 anniversary of the first Banff Classification, pre-meeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • - Alloimmune injury is a significant cause of long-term failure in kidney transplants, occurring due to either cellular or antibody-mediated rejection, and early detection is crucial for maintaining kidney function.
  • - Traditional measures of kidney function, like serum creatinine levels, fall short in identifying immune monitoring issues, highlighting the need for more effective biomarkers.
  • - New biomarkers are being utilized to improve detection of both clinical and subclinical rejection, predict rejection risks, and tailor immunosuppressive treatments, but challenges remain regarding their clinical application and validation.
View Article and Find Full Text PDF